Drug intelligence / Profile preview

N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide

Development stage
Unknown
Modality
Small Molecules
01

Overview

N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide is an experimental small molecule belonging to the biphenyldicarboxamides chemical class. It has a molecular formula of C22H24N2O2 and a molecular weight of approximately 348.44 g/mol[1][2][8]. The compound has been studied as a potent inhibitor of mitogen‑activated protein kinase 14 (MAPK14/p38α), with reported IC50 and Ki values in the low nanomolar range[1]. It also shows inhibitory activity against cytochrome P450 enzymes CYP2C19 and CYP1A2 at higher concentrations[6]. There are no approved indications or clinical trials beyond preclinical/experimental stages for this compound.

Other names
N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide[1,1′-Biphenyl]-3,4′-dicarboxamide, N3-cyclopropyl-N4′-(cyclopropylmethyl)-6-methyl-515134-70-0 (CAS number)
02

Targets

CYP3A4 (Cytochrome P450 3A4)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call